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Abstract
Epitope-based vaccines (EVs) have a wide range of applications: from therapeutic to prophylactic approaches, from
infectious diseases to cancer. The development of an EV is based on the knowledge of target-specific antigens from which
immunogenic peptides, so-called epitopes, are derived. Such epitopes form the key components of the EV. Due to
regulatory, economic, and practical concerns the number of epitopes that can be included in an EV is limited. Furthermore,
as the major histocompatibility complex (MHC) binding these epitopes is highly polymorphic, every patient possesses a set
of MHC class I and class II molecules of differing specificities. A peptide combination effective for one person can thus be
completely ineffective for another. This renders the optimal selection of these epitopes an important and interesting
optimization problem. In this work we present a mathematical framework based on integer linear programming (ILP) that
allows the formulation of various flavors of the vaccine design problem and the efficient identification of optimal sets of
epitopes. Out of a user-defined set of predicted or experimentally determined epitopes, the framework selects the set with
the maximum likelihood of eliciting a broad and potent immune response. Our ILP approach allows an elegant and flexible
formulation of numerous variants of the EV design problem. In order to demonstrate this, we show how common
immunological requirements for a good EV (e.g., coverage of epitopes from each antigen, coverage of all MHC alleles in a
set, or avoidance of epitopes with high mutation rates) can be translated into constraints or modifications of the objective
function within the ILP framework. An implementation of the algorithm outperforms a simple greedy strategy as well as a
previously suggested evolutionary algorithm and has runtimes on the order of seconds for typical problem sizes.
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Introduction
The development of vaccines and their subsequent large-scale
prophylactic use was undoubtedly one of the most important
developments in medicine. Vaccines make use of the adaptive part
of the human immune system to protect from future infections
(e.g., prophylactic vaccines used against viruses) as well as to fight
chronic diseases and cancer.
Cellular adaptive immunity is, at its core, triggered by the
recognition of immunogenic peptides bound to MHC class I
(MHC I) and II molecules by T-cell receptors located on the
surface of T cells. These peptides are derived from antigens, i.e.,
proteins that can cause an immune response, as a result of rather
complex antigen processing pathways in vivo. Peptides capable of
causing such an immune response are called epitopes and
represent the smallest subunits that may be used therapeutically.
There are numerous options for constructing a vaccine once a
set of potential antigens is known. The antigens or parts thereof
can be used as intact proteins [1,2], they can be administered as
RNA or DNA coding for the antigen [3,4], or the epitopes
contained in the antigens may be used for vaccines. As discussed in
detail in [5] the use of epitope-based vaccines (EVs) brings about
manifold advantages, e.g., safety, ease of production, analytical
control, and distribution. Skilled selection of epitopes can precisely
direct the evoked immune response at conserved and highly
immunogenic regions of several antigens. Due to these advantages
and the applicability in personalized vaccination, EVs have
recently been getting more and more attention. The recent review
of EVs by Purcell et al. [5] gives a good overview of the state of the
art as well as its achievements. We will thus only point out some
recent studies.
EVs have proven successful in preclinical trials in mice [6], on
which many of the preliminary studies have been conducted. A
large number of clinical studies, both from academia and industry,
have also been successful and have entered and/or completed
clinical phase I and II trials [7–11]. Several commercial products
have now entered clinical phase III trials. The indications for the
vaccines in trial are mostly various cancers (e.g., leukemia,
colorectal cancer, gastric cancer, lung cancer) and infectious
diseases (predominantly HIV and hepatitis C virus).
The design of an EV entails one critical step, the selection of the
epitopes. From the set of antigens, one can experimentally
determine or computationally predict epitopes for a variety of
MHC alleles. The crucial task is to select the set of epitopes which
yields the best immune response in a given population while at the
same time keeping the number of epitopes low. This step is of
course critical to the success of the vaccine. The selection is usually
made on a case-by-case basis considering key properties for each
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coverage, antigen coverage, and antigen processing.
The selection methods used by the pharmaceutical industry are
manifold. In 2004, Singh-Jasuja et al. presented the Tu ¨bingen
approach [12] to acquire an experimentally validated initial list of
epitopes from tumor associated antigens. In this work, the
incorporation of computational methods for prediction of MHC-
peptide binding in the process is proposed. Since they help to
reduce the number of experiments to be performed, such
prediction methods have become standard tools in immunology.
Commonly used methods are SYFPEITHI [13], HLA_BIND/
Bimas [14], SVMHC [15], NetMHC [16–18], EpiMatrix [19],
and the methods [20–23] provided by the Immune Epitope
Database [24].
Given the set of candidate peptides, computational methods can be
used to determine the relevant attributes of each candidate. However,
the final choice of the set of epitopes to be used in the vaccine is
typically performed manually. Several groups have addressed this
problem computationally. In 2005, DeGroot et al. [25] published an
approach to creating highly immunogenic and conserved epitopes to
be used in EVs. The authors use EpiMatrix [19] to estimate the
MHC class II binding affinity of highly conserved 9mers from HIV-1
proteins. Peptides with high binding affinities are then used to
construct extended peptides containing multiple overlapping 9mers.
In vitro evaluation of the immunogenicity of a selected set of these
extended peptides yielded positive results.
Recently, Vider-Shalit et al. [26] proposed using a genetic
algorithm to design an ordered sequence of epitopes to be used in
an EV. Information on peptide conservation and similarity to self-
peptides is used to pre-filter the set of candidates, while
information on MHC allele frequencies is used to select alleles
of interest. The scoring function used for the heuristic takes into
account the number of covered MHC alleles, the number of
covered antigens, the number of covered MHC/antigen combi-
nations, and the probability of each epitope to be properly cleaved
in the sequence.
Two related approaches were published by Fischer et al. [27]
and Nickle et al. [28]. Both groups focus on designing vaccine
antigens capable of protecting against diverse HIV-1 strains. In
order to do so, they use computational methods to compress the
variation found in naturally occurring antigens into a small
number of composite antigens.
Common to the computational approaches above (and of course
manual selection) is the fact that the solutions are not necessarily
optimal. None of the approaches can guarantee that there is not a
better vaccine possible from the given set of epitopes. In this work
we propose an integer linear programming approach to finding a
provably optimal set of epitopes for an EV. Given a set of
candidate peptides, a set of MHC alleles of interest, information
on the peptides’ respective immunogenicities along with other
information to be incorporated into the selection process, our
framework is capable of finding the set of epitopes yielding the
highest possible overall immunogenicity (Figure 1). The resulting
integer linear program can be solved very efficiently for all
practical problem sizes (runtimes of a few seconds) and can thus be
readily applied. With respect to various quality criteria (population
coverage, antigen coverage, overall immunogenicity), the ap-
proach outperforms a simple greedy heuristic (‘pick the k best
epitopes’) and also a genetic algorithm. The elegant mathematical
formulation turns out to be flexible enough to also account for
variants of the problem, e.g., the application to personalized
vaccines. To our knowledge, this is the first epitope selection
framework that finds the optimal solution.
Materials and Methods
Approach
In order to find an optimal set of epitopes, we first have to
define what characterizes a good vaccine or, correspondingly, a good
set of epitopes. This issue is highly controversial in the literature
and only large-scale data from vaccination trials will provide
sufficient data to validate the different approaches retrospectively.
With this in mind, we do not suggest one optimal epitope selection
strategy, but instead suggest a mathematical framework that allows
working with various definitions of the term ‘good vaccine’. For a
chosen definition, however, the algorithms will yield a combina-
tion of epitopes that is provably optimal.
In the following, we will introduce a ‘reasonable’ definition of a
good vaccine. This will allow us to present the mathematical
formulation and to illustrate how immunological requirements can
be translated into mathematical constraints. For specific applica-
tions, the requirements and constraints may of course deviate from
thosegiven.Forexample,sequencevariationinanantigenwouldbe
much more important for an HIV vaccine than for a cancer
vaccine.The frameworkisflexibleenoughtoallowforsuchdifferent
requirements, as we will illustrate towards the end of the work.
A good vaccine displays a high overall immunogenicity, which
means it is capable of inducing potent immunity in a large fraction of
the target population. This basic definition forms the basis of our
mathematical formulation which aims at maximizing overall
immunogenicity of the selected epitopes. We extend this definition
by additionally requiring high mutation tolerance as well as a certain
degree of allele and antigen coverage. Furthermore, the selected
epitopes should display a high probability of passing through the
antigen processing pathway. We thus obtain a brief list of basic
requirements:
Mutation tolerance. Mutations within the targeted antigen
regions can lead to an escape from immune response. High genetic
variability as observed in, e.g., HIV, the hepatitis C virus, and
influenza can thus affect protection by a vaccine. Selection of highly
Author Summary
Over the last decade the design of tailor-made vaccines for
prophylactic applications (e.g., prevention of infection) and
therapeutic applications (e.g., cancer therapy) has attract-
ed significant interest. Epitope-based vaccines are good
candidates for such tailor-made approaches. They trigger
an immune response by confronting the immune system
with immunogenic peptides derived from, e.g., viral- or
cancer-specific proteins. These peptides bind to major
histocompatibility complex (MHC) molecules in a specific
manner. The resulting complex is crucial for immune
system activation. However, there are many allelic variants
of MHC molecules, meaning that different patients
typically bind different repertoires of peptides. Neverthe-
less, due to economical and regulatory issues one cannot
simply add all immunogenic peptides to such a peptide
mix. Hence, it is crucial to identify the optimal set of
peptides for a vaccine, given constraints such as MHC
allele frequencies in the target population, peptide
mutation rates, and maximum number of selected
peptides. In this work we formalize this problem, and
variants thereof, in a mathematical framework. The
resulting optimization problem can be solved efficiently
and yields a provably optimal peptide combination. We
can show that the method performs better than existing
solutions. Furthermore, the framework is highly flexible
and can easily handle additional criteria.
Selection of Optimal Peptide Sets for Vaccines
PLoS Computational Biology | www.ploscompbiol.org 2 December 2008 | Volume 4 | Issue 12 | e1000246conserved non-overlapping epitopes reduces the chance of immune
escape.
Allele coverage. Because the MHC is polygenic, every
individual possesses a set of MHC loci. Due to the high
polymorphicity of these loci, the pool of MHC molecules varies
from individual to individual. The allelic form of an MHC
molecule determines the spectrum of peptides the molecule can
bind. Within a population alleles occur with different frequencies.
Hence, requiring a certain number of alleles to be covered is
equivalent to requiring a certain degree of population coverage.
An MHC allele is said to be covered by a set of epitopes if at least
one of the epitopes is capable of inducing an immune response
when bound to the corresponding MHC molecule.
Antigen coverage. The expression frequencies of viral
proteins differ. Selecting epitopes from a wide variety of antigens
increases the chance of detecting a virus at any developmental
stage.
Antigen processing. Before a peptide is presented by an
MHC molecule on the cell surface it passes through an antigen
processing pathway, which includes proteasomal cleavage and
TAP transport. Knowledge of these steps’ specificities allows
exclusion of peptides which are unlikely to ever be presented to a
T cell.
From all possible epitope combinations, the ones with a
maximum overall immunogenicity will be called ‘optimal’ (there
may be more than one optimal epitope combination). Hence, the
search for an optimal epitope set for an EV can be interpreted as
an optimization problem: out of a given set of epitopes, choose a
subset which, out of all subsets meeting the above-named
requirements, displays maximum overall immunogenicity. Since
health agencies such as the FDA require proof of the effectiveness
and safety of every individual component of a vaccine, the size of
such a subset is usually kept rather small (up to a dozen peptides).
Mathematical Abstraction
Given a set of epitopes and a set of MHC alleles we assume a
linear relationship to exist between (a) the immune response
induced by all epitopes with respect to all alleles and (b) the
immune responses induced by every single one of the epitopes
with respect to each of the alleles. Thus, the overall immunoge-
nicity of a set of epitopes depends on the immunogenicity of its
components with respect to the different MHC alleles. Further-
more, the contribution of an allele directly depends on its
probability of occurring within the target population. (In this
context probability is commonly referred to as frequency. We use
probability since it is the mathematically correct term.) More
common alleles are weighted more than uncommon ones. Thus,
overall immunogenicity I can be derived mathematically as a
weighted sum over immunogenicities of epitopes E with respect to
the given MHC alleles A:
I~
X
e[E
X
a[A
pa:ie,a
where pa corresponds to the probability of allele a in the target
population and ie,a to a measure of the immunogenicity of epitope
e when bound to allele a (either experimentally determined or
predicted).
Integer Linear Programming
Our goal is to maximize overall immunogenicity while
constraining the possible solutions to sets of peptides which satisfy
the above mentioned requirements for a good vaccine. This
problem can be conveniently formulated as an integer linear
program (ILP). Linear programming deals with the optimization of
linear objective functions subject to linear constraints [29]. An ILP
is a linear program with integral unknowns. While linear programs
Figure 1. Basic idea behind this work. Starting from target antigens, a list of properties of interest, and a target population the information
necessary to determine an optimal set of epitopes is derived (gray boxes). Given this information, a mathematical framework can conveniently be
used to find the set of epitopes that is optimal with respect to the target population and the properties of interest.
doi:10.1371/journal.pcbi.1000246.g001
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PLoS Computational Biology | www.ploscompbiol.org 3 December 2008 | Volume 4 | Issue 12 | e1000246without integral unknowns can be solved efficiently, ILPs are NP-
complete. Nevertheless, there are tools available that find optimal
solutions quite efficiently.
We restate the problem of choosing the optimal set of epitopes
as an ILP. Solving the ILP will render an optimal solution
according to our definition of an optimal epitope set. (Adapting the
ILP to a different definition is straightforward.) For the sake of
clarity, we start out with the very basic definition of an optimal
epitope set. In the next step the resulting ILP will be extended to
represent the more refined definition.
The set of candidate epitopes is E. Each epitope eME is
associated with a binary decision variable xe, where xe=1 if the
respective epitope belongs to the optimal set and xe=0 otherwise.
The ILP corresponding to the basic definition of an optimal
epitope set is shown in Table 1. This ILP maximizes overall
immunogenicity: epitope immunogenicity with respect to a specific
MHC allele is weighted by the allele’s probability. The only
constraint is the number of epitopes to select.
We will now extend this basic ILP to represent a more refined
definition of a good epitope set. In order to implement the
additional requirements we introduce another set of binary
decision variables: each MHC allele a is associated with a variable
ya. If allele a is covered, meaning that an epitope which is
sufficiently immunogenic with respect to allele a belongs to the
optimal set, ya=1, otherwise ya=0. The extended ILP is shown in
Table 2. It accounts for mutation tolerance by selecting only non-
overlapping conserved epitopes, and for allele and antigen
coverage. Additional constraints prevent the selection of peptides
which are unlikely to result from antigen processing.
It might be desirable to obtain several optimal or nearly optimal
epitope sets. As proposed in [30], this can be achieved by adding
the constraints given in eq. (1), where Sj represents the optimal set
of epitopes found in iteration j and s represents the number of
solutions to be obtained. The ILP has to be solved iteratively s
times. After each iteration, the ILP for the next iteration j+1i s
created by adding the corresponding constraint to the ILP of
iteration j.
X
u[Sj
xuƒk{q forj~1...s{1 ð1Þ
Every resulting epitope set differs from all other solutions in at
least q peptides, 1#q#k.
Nonlinear Requirements
In order to incorporate a requirement into the ILP framework it
must be formulated as a linear constraint. There are, however,
reasonable requirements which are non-linear. These cannot be
incorporated directly. It is possible though to search a sufficiently
large set of optimal and suboptimal solutions for the best set of
epitopes that yields the required properties—provided that the
requirements are feasible. Two examples of reasonable non-linear
requirements will be discussed below.
Example 1: Population coverage. A major interest in
vaccine design is population coverage: For what fraction of a
target population will the resulting EV be effective? In theory this
corresponds to the probability of an individual in the population
carrying at least one MHC allele covered by the epitopes in the
EV. Given a set of MHC alleles A as before and their distribution
within a population, the population coverage of a particular set of
epitopes can be computed. For this computation the polygenicity
of the MHC has to be taken into account. It is A=A1 <…< Am
with Ai being the alleles at locus i. Let pL
a be the probability of an
allele a occurring at the corresponding MHC locus. Then the
probability of an individual in the population carrying an allele
from the set Ai at locus i corresponds to
pL
Ai~1{ 1{
X
a[Ai
pL
a
 ! 2
:
Let ya be as described above. It follows that the probability of an
individual carrying at least one MHC allele covered by the
epitopes in E, and thus the population coverage of E,i s
pcE~1{ P
m
i~1
1{
X
a[Ai
yapL
a
 ! 2
:
Example 2: Average number of epitopes per
individual. Population coverage of an epitope set states what
fraction of a population carries an MHC allele associated with one
of the epitopes. It does not give any information on the number of
active epitopes per individual. The number of epitopes within a set
which are active for a specific individual depends on the
individual’s MHC genotype. Given the haploidic probabilities of
MHC alleles within a population the probability of MHC
genotypes can be calculated. Alleles not included in the set A are
accounted for by adding a representative allele X to each locus.
The frequency of the representative at locus i results from
pL
Xi~1{
P
a[AipL
a.
Let G be the set of genotypes within the population of interest
and pg the probability of genotype g. Furthermore, let bg be the
number of epitopes in an epitope set E which are immunogenic
with respect to an MHC allele in g. The average number of active
Table 1. ILP corresponding to the basic definition of an
optimal epitope set.
Definitions
A Set of observed MHC alleles
E Set of candidate epitopes
Parameters
ie,a Immunogenicity of epitope e with respect to allele a
k Number of epitopes to select
pa Probability of MHC allele a occurring in the target
population
Variables
xe=1 If epitope e belongs to the optimal set, otherwise
xe=0
Integer Linear Program
Maximize Maximize …
geMExegaMApa ie,a … Overall immunogenicity
subject to
geMExe=k … And select exactly k peptides.
doi:10.1371/journal.pcbi.1000246.t001
Selection of Optimal Peptide Sets for Vaccines
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y E ðÞ ~
X
g[G
pg bg:
Evaluation
Vider-Shalit et al. [26] applied their evolutionary-algorithm-
based vaccine design method to hepatitis C virus (HCV). We used
our framework on similar data and compared the results of both
approaches.
Data. HCV protein sequences (amino acid frame 1) for ten
different proteins (C, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A,
NS5B) and four different subtypes (1a, 1b, 2a, 3a) were retrieved
from the Los Alamos hepatitis C sequence database [31]. For each
protein of each subtype a multiple sequence alignment (MSA) was
created using MUSCLE [32], resulting in 40 MSAs. From each
MSA a consensus sequence was created. All 9mers from these
consensus sequences were regarded as potential epitopes. In silico
predicted MHC binding affinities using BIMAS matrices [14] are
utilized as a measure of immunogenicity. MHC alleles, their
probability of occurring in the human population, and binding
affinity score thresholds were directly taken from Vider-Shalit et al.
To allow a comparison of our results with those of Vider-Shalit et
al., we adopt their simplistic definition of peptide conservation (A
peptide is considered to be at least x% conserved if all of its amino
acids display a conservation of at least x%.) and disregard all
insufficiently conserved (,90%) peptides. To score the probability
of a peptide being a result of antigen processing, we used the
proteasomal cleavage matrix from the supplementary material of
[26]. As noted in several places, the influence of TAP transport is
often rather limited [26,33]. Consideration of TAP transport is
thus omitted for this example.
It has to be noted that the accuracies of the prediction methods
cause some limitations. MHC-peptide binding can be predicted
with relatively high accuracy for many alleles, whereas proteaso-
mal cleavage prediction leaves more room for improvement.
Incorporating the scoring function. The scoring function S
of Vider-Shalit et al. takes into account the number of covered
Table 2. ILP corresponding to the extended definition of an optimal epitope set.
Definitions
A Set of observed MHC alleles
Ei Set of epitopes from the i-th antigen
E Set of all candidate epitopes (E=E1 <…< En)
Ia Set of epitopes which, when bound to an MHC allele a, display an immunogenicity greater than or equal to a given threshold t
I
I Set of all sufficiently immunogenic epitopes (I=<aMAIa)
O Set of overlapping pairs of epitopes
Parameters
ce Conservation of epitope e
ie,a Immunogenicity of epitope e with respect to allele a
k Number of epitopes to select
pa Probability of MHC allele a occurring in the target population
pAP
e Probability that epitope e will be produced during antigen processing
t
A Minimum number of epitopes from each antigen to be included
t
AP Antigen processing threshold
t
C Conservation threshold
t
MHC Minimum number of MHC alleles to be covered
Variables
xe=1 If epitope e belongs to the optimal set, otherwise xe=0
ya=1 If allele a is covered by the optimal set, otherwise ya=0
Integer Linear Program
Maximize Maximize …
geMExegaMApa ie,a … Overall immunogenicity.
subject to
geMExe=k Selects exactly k epitopes.
;eME:( 1 2ce)xe#(12t
C) Ensures certain degree of epitope conservation.
;(p, r)MO:x p+xr#1 Guarantees that selected epitopes do not overlap.
;aMA:
P
e[Iaxe§ya Guarantees that ya=1 only if allele a is covered.
gaMAya$t
MHC Enforces required allele coverage.
;iM{1,…,n}:
P
e[Ei\Ixe§tA Enforces required antigen coverage.
;eME: 1{pAP
e
  
xeƒ 1{tAP   
Selects only epitopes which have a chance of at least t
AP to result from
antigen processing.
doi:10.1371/journal.pcbi.1000246.t002
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covered MHC/antigen combinations, and a score for the
probability of each epitope in the ordered sequence being
properly cleaved:
Ss ðÞ ~ 2:6:#covered antigensz0:77:#covered allelesz ð
#covered combinationsÞ:p cleave ðÞ :
Here, s represents the ordered sequence of epitopes to be scored.
In order to show the flexibility of our approach we incorporate
aspects of this function in our ILP. Since the aim of our framework
is to select a set of epitopes and not to create an epitope sequence,
we omit the factor p(cleave).
Binary variables have to be introduced in order to count the
number of covered antigens and the number of covered MHC/
antigen combinations: zi=1 if an epitope from the i-th antigen
belongs to the optimal set and zi=0 otherwise. wa,i=1 if an
epitope from the i-th antigen, which is sufficiently immunogenic
with respect to MHC allele a, belongs to the optimal set and
wa,i=0 otherwise. Since immunogenicity scores tend to be higher
than the weighted sums of the coverage scores and would therefore
outweigh them, we scale the immunogenicity by a (purely
empirical) factor of 0.1. The resulting ILP still aims at high
overall immunogenicity while at the same time extending the
coverage of antigens, MHC alleles, and MHC/antigen combina-
tions. The ILP is shown in Table 3.
Implementation
We used ILOG CPLEX 9.1 [34] with its C++ interface ILOG
Concert Technology 2.1 to formulate and solve the ILP. It is,
however, possible to solve the ILPs with most other ILP solvers,
e.g., MOSEK [35] or freely available packages like SCIP [36,37].
A formulation of the extended ILP (Table 2) as ILOG CPLEX
input, the required data for the comparison with Vider-Shalit et al.
[26] as well as the corresponding ILOG CPLEX output can be
found in the supplementary material (Texts S1, S2, S3).
Results
Immunogenicity
In order to show the effectiveness of the above-mentioned
approach, we compare our strategy with other published
approaches and determine the theoretical gain in immunogenicity
or the number of epitopes required to achieve a similar
immunogenicity. While an experimental validation of this
approach would be valuable, it is beyond the scope of this paper,
which focuses on the theoretical foundations of the epitope
selection. We compare our optimal strategy (best overall
immunogenicity, BOI) with two simple approaches:
N randomly select k peptides out of a pool of good epitopes
(random set of epitopes, RSE) and
N a simple greedy approach: pick the k best epitopes from the set
(best epitope-wise immunogenicity, BEI).
Table 3. ILP corresponding to the combined optimization problem.
Definitions
A Set of observed MHC alleles
Ei Set of epitopes from the i-th antigen
E Set of all candidate epitopes (E=E1 <…< En)
Ia Set of epitopes which, when bound to an MHC allele a, display an immunogenicity greater than or equal to a given threshold t
I
I Set of all sufficiently immunogenic epitopes (I=<aMAIa)
Parameters
ie,a Immunogenicity of epitope e with respect to allele a
pa Probability of MHC allele a occurring in the target population
Variables
wa,i=1 If allele a is covered by an epitope from the i-th antigen, otherwise wa,i=0
xe=1 If epitope e belongs to the optimal set, otherwise xe=0
ya=1 If allele a is covered by the optimal set, otherwise ya=0
zi=1 If an epitope from the i-th antigen belongs to the optimal set, otherwise zi=0
Integer Linear Program
Maximize Maximize …
0.1?geMExegaMApa ie,a + … Overall immunogenicity and …
2:6:Pn
j~1 zjz0:77:P
a[Ayaz … Extend coverage of antigens,
MHC alleles, …
P
a[A
Pn
j~1 wa,j … And MHC/antigen combinations.
Subject to
All constraints from the extended ILP (Table 2)
;iM{1,…,n}
P
e[Ei\Ixe§zi Ensures that zi=1 only if the i-th
antigen is covered.
;iM{1,…,n} aMA
P
e[Ei\Iaxe§wa,i Ensures that wa,i=1 only if allele a is
covered by an epitope from the i-th
antigen.
doi:10.1371/journal.pcbi.1000246.t003
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different-sized sets of epitopes from a set of 4461 conserved
($90%) HCV 9mers. For BOI the basic ILP (Table 1) was used to
maximize overall immunogenicity. BEI selects the epitopes with
the highest sum of immunogenicities irrespective of the probabil-
ities of the corresponding MHC alleles. The overall immunoge-
nicity of each epitope set was determined and is displayed in
Figure 2. For RSE, mean and standard deviation of 100 random
selections of different-sized epitope sets from the 100 most
immunogenic peptides are shown. The BEI curve shows sudden
increases in overall immunogenicity from 0 to 1, 10 to 13, and
from 20 to 21 epitopes. This is caused by the selection of epitopes
which are highly immunogenic with respect to HLA-A*0201,
which is the most common (p
L=0.145) among the considered
alleles. All other selected epitopes are highly immunogenic with
respect to less common alleles like HLA-B*2705 (p
L=0.015) or
HLA-B*5102 (p
L=0.003). Thus the former contribute more
extensively to the overall immunogenicity than the latter.
The average overall immunogenicity of the randomly chosen
epitope sets is rather low: scores range from about 308 for five
epitopes, to 1,763 for 25 epitopes, to 2,699 for 40 epitopes. The
other two approaches start from a minimum overall immunoge-
nicity of more than 900 and reach immunogenicities of 4,502 (BEI)
and 6,142 (BOI), respectively. To achieve an immunogenicity of at
least 2,699, BOI requires five and BEI 12 epitopes (Figure 2).
For sets with more than one epitope, the scores yielded by the
BOI strategy are between about 20% (13 epitopes) and 120% (6
epitopes) higher than those of the BEI strategy.
Comparison with Vider-Shalit et al. on HCV
In order to compare our approach to the work of Vider-Shalit et
al.[26] we applied theILPgiveninTable 2 to the HCVdata and 27
of the 29 alleles from [26]. The alleles HLA-B
*0702 and HLA-
B
*3501 were omitted, since none of the candidate peptides binds to
them. Probably due to an error in sequence processing (personal
communication with Yoram Louzoun), a peptide (AALENLVTL)
which does not belong to any of the proteins under consideration
was included in the 25 epitopes selected by Vider-Shalit et al. We
exclude this peptide and base our comparison on sets of 24 epitopes.
For the 24 epitopes to be selected, we require a minimum
conservation of 90%, an allele coverage of 27, and an antigen
coverage of at least one epitope per antigen. Furthermore, only
epitopes with antigen processing scores within the top 30% of all
sufficiently conserved candidate peptides were allowed to be
selected. The following 24 epitopes (hereafter EILP) were selected:
Four epitopes (marked with *) are known HCV epitopes and
can be found in the Immune Epitope Database (IEDB, release
2008_4_1_3_28) [24]. Another 11 epitopes (marked with +) are
contained in known longer epitopes. The overall immunogenicity
of the selected set is 2,549. It includes binders for all 27 alleles with
all 40 antigens being represented and covers 22.7% of all MHC/
antigen combinations. The average number of epitopes per
individual of the population is 13.3. The corresponding values of
the epitope set selected by Vider-Shalit et al. (hereafter EVS) are
listed in Table 4.
To improve the MHC/antigen coverage while still aiming at
high overall immunogenicity we included the central part of the
scoring function of Vider-Shalit et al. in the objective function of
our ILP. The optimal epitope set with respect to the modified
objective function (hereafter EComb) is only 15% less immunogenic
than the original epitope set EILP and more than 17 times more
immunogenic than EVS. As for MHC/antigen coverage, it
outperforms both (Table 4). EComb includes one epitope which is
already known and 14 epitopes which are contained in longer
epitopes listed in the IEDB. Figure 3 shows that when using the
Figure 2. Comparison of different epitope selection strategies with respect to overall immunogenicity. (A) Overall immunogenicity of
different-sized epitope sets. (B) Overall immunogenicity of a set of 10 epitopes. (C) Number of epitopes required to achieve an overall
immunogenicity of at least 2,699.
doi:10.1371/journal.pcbi.1000246.g002
SFSIFLLAL
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*
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+
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+ IELGGKPAL
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+ KLLPRLPGV RHTPVNSWL
+
WPLLLLLLA VTYSLTGLW YFVIFFVAA
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and antigens and furthermore to outperform EVS in terms of
immunogenicity (371) and MHC/antigen coverage (22.8%).
Discussion
The selection of an epitope set with very high overall
immunogenicity is crucial for the efficacy of an EV. Depending
on the number of candidate epitopes to choose from, the number
of alleles to be considered, as well as on the additional
requirements, this problem can become very complex. In this
work we propose a mathematical framework that can be used to
solve this problem quickly for practical problem sizes. For several
characteristic examples, we show that immunological require-
ments can be conveniently formulated as an ILP. The solution of
this ILP yields an optimal set of epitopes: the set of epitopes that
displays the highest overall immunogenicity of all sets which meet
the pre-defined requirements. To our knowledge, this is the only
approach that yields provably optimal solutions to the vaccine
design problem for EVs. In contrast to previous heuristics, the
optimal solution yields either significantly better overall immuno-
genicity for the same number of epitopes or a smaller number of
required epitopes to reach the same level of immunogenicity. The
flexibility of the framework allows selecting other objective
functions, too, for example, maximizing antigen or allele coverage.
The optimal selection of epitopes yields—in theory—signifi-
cantly higher overall immunogenicities than other strategies (e.g.,
selection of the best epitopes or evolutionary algorithms).
However, one should keep in mind that the selection of the
epitopes is still a difficult and controversial issue since the
underlying processes are not yet fully understood. In particular,
the interplay of different epitopes poses a difficult problem.
Competition between epitopes will probably result in reduced
immunogenicity of peptide cocktails, an effect that has been
observed in various studies.
On the one hand, this represents a problem, because the
assumption of independence between epitopes is one of the key
assumptions made in this work (and in all related approaches).
Lacking an accurate model of these competition effects, however,
it seems like the best assumption one can make. On the other
hand, the effects of competition are a compelling reason to employ
this type of selection approach. Competition effects will be less
severe for fewer peptides, therefore a selection procedure that
yields the same overall immunogenicity with fewer peptides can in
fact mitigate this problem. Assuming that competition primarily
arises between epitopes binding to the same MHC allele, one can
also introduce additional constraints to reduce competition (e.g.,
find the best combination that contains at most two epitopes per
allele). In the long run, a thorough quantitative analysis of larger
vaccination studies might shed some light on these effects and their
importance.
Also, the notion of immunogenicity alone, or the ability to evoke
an immune response in a certain fraction of patients, is not
necessarily a true measure of quality for a vaccine. In their recent
review on the quality of the T-cell response [38], Seder et al. argue
Table 4. Overview over properties of HCV epitope sets
selected using different strategies.
EILP EVS EComb
Overall immunogenicity 2,549 125 2,177
Allele coverage 100% 96.3% 100%
Antigen coverage 100% 87.5% 100%
MHC/antigen coverage 22.7% 19.2% 30.5%
Population coverage 96.0% 95.6% 96.0%
Avg. number of epitopes per individual 13.3 11.4 17.3
Number of epitopes in IEDB 4 11
Number of epitopes per set: 24. EILP: set selected by our ILP, EVS: set selected by
Vider-Shalit et al. without peptide AALENLVTL, EComb: set selected by our ILP
extended by aspects of the scoring function of Vider-Shalit et al.
doi:10.1371/journal.pcbi.1000246.t004
Figure 3. Comparison of properties of HCV epitope sets selected using different strategies. (A) Overall immunogenicity. (B) Coverage of
MHC/antigen pairs.
doi:10.1371/journal.pcbi.1000246.g003
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described by a measure of magnitude alone. An adequate metric
would thus not only account for the magnitude but also for the
multifunctional quality of the response. The flexibility of our
framework allows for the incorporation of a different quality
measure for immunogenicity and a careful comparison of the
peptide cocktails suggested by different objective functions would
be very interesting.
In their review of EVs, Purcell et al. [5] point out that, to date,
there are no human EVs on the market. This is mainly attributed
to the difficulties associated with peptide stability and delivery.
Various delivery strategies [39] are being explored in clinical
studies. In an extension of this work, one might therefore also
include considerations related to the peptide delivery. For beads-on-
a-string type vaccines, the selected epitopes are combined into one
larger polypeptide. As the specificities of the antigen processing
pathway have to be taken into account when constructing the
polypeptide, the order of the epitopes as well as possible spacer
sequences need to be optimized (e.g. through incorporation of a
proteasomal cleavage matrix).
Supporting Information
Text S1 ILOG CPLEX input. AMPL formulation of the
extended ILP given in Table 2 adapted for the comparison with
Vider-Shalit et al.
Found at: doi:10.1371/journal.pcbi.1000246.s001 (3.00 KB TXT)
Text S2 HCV data (in AMPL format) used for the comparison
with Vider-Shalit et al. Only highly conserved peptides (.=90%)
were considered when generating this file.
Found at: doi:10.1371/journal.pcbi.1000246.s002 (1.70 MB
TXT)
Text S3 ILOG CPLEX output.
Found at: doi:10.1371/journal.pcbi.1000246.s003 (2.00 KB TXT)
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